← All trials
NCT04855305
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 12, 2021
- Primary completion
- Mar 31, 2025
- Completion date
- Mar 31, 2025
- First posted
- Apr 22, 2021
- Last posted
- Nov 16, 2021
- Enrollment
- 147
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Duke UniversityLead sponsor
- Duke UniversitySponsor investigator
- Duke UniversityOverall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- University of IowaCollaborator
- University of CincinnatiCollaborator
- University of CincinnatiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.